These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question. Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Meltzer L; Kurukulasuriya NC Mult Scler; 2015 Jan; 21(1):57-66. PubMed ID: 24990854 [TBL] [Abstract][Full Text] [Related]
30. Dimethyl fumarate for treating relapsing multiple sclerosis. Sheremata W; Brown AD; Rammohan KW Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392 [TBL] [Abstract][Full Text] [Related]
31. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies. Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185 [TBL] [Abstract][Full Text] [Related]
32. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Deeks ED Drugs; 2016 Feb; 76(2):243-54. PubMed ID: 26689201 [TBL] [Abstract][Full Text] [Related]
33. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Singer BA; Arnold DL; Drulovic J; Freedman MS; Gold R; Gudesblatt M; Jasinska E; LaGanke CC; Naismith RT; Negroski D; Oh J; Hernandez Perez MA; Selmaj K; Then Bergh F; Wundes A; Ziemssen T; Castro-Borrero W; Chen H; Levin S; Scaramozza M; Shankar SL; Wang T; Wray S Mult Scler; 2023 Dec; 29(14):1795-1807. PubMed ID: 37905526 [TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. Su W; Kansal A; Vicente C; Deniz B; Sarda S J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475 [TBL] [Abstract][Full Text] [Related]
38. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304 [TBL] [Abstract][Full Text] [Related]
39. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Blair HA Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875 [TBL] [Abstract][Full Text] [Related]